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BACKGROUND
Silent cerebral infarcts are the most common neurologic injury in children with 
sickle cell anemia and are associated with the recurrence of an infarct (stroke or 
silent cerebral infarct). We tested the hypothesis that the incidence of the recur-
rence of an infarct would be lower among children who underwent regular blood-
transfusion therapy than among those who received standard care.
METHODS
In this randomized, single-blind clinical trial, we randomly assigned children with 
sickle cell anemia to receive regular blood transfusions (transfusion group) or 
standard care (observation group). Participants were between 5 and 15 years of age, 
with no history of stroke and with one or more silent cerebral infarcts on mag-
netic resonance imaging and a neurologic examination showing no abnormalities 
corresponding to these lesions. The primary end point was the recurrence of an 
infarct, defined as a stroke or a new or enlarged silent cerebral infarct.
RESULTS
A total of 196 children (mean age, 10 years) were randomly assigned to the observa-
tion or transfusion group and were followed for a median of 3 years. In the trans-
fusion group, 6 of 99 children (6%) had an end-point event (1 had a stroke, and 5 had 
new or enlarged silent cerebral infarcts). In the observation group, 14 of 97 chil-
dren (14%) had an end-point event (7 had strokes, and 7 had new or enlarged silent 
cerebral infarcts). The incidence of the primary end point in the transfusion and 
observation groups was 2.0 and 4.8 events, respectively, per 100 years at risk, cor-
responding to an incidence rate ratio of 0.41 (95% confidence interval, 0.12 to 
0.99; P = 0.04).
CONCLUSIONS
Regular blood-transfusion therapy significantly reduced the incidence of the recur-
rence of cerebral infarct in children with sickle cell anemia. (Funded by the Na-
tional Institute of Neurological Disorders and Stroke and others; Silent Cerebral 
Infarct Multi-Center Clinical Trial ClinicalTrials.gov number, NCT00072761, and 
Current Controlled Trials number, ISRCTN52713285.)
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Sickle cell anemia affects 1 of every 3961 black newborns and approximately 100,000 persons in the United States.2,3 
Among children with sickle cell anemia (defined 
as homozygous hemoglobin S or hemoglobin 
S-β0 thalassemia), silent cerebral infarcts are the 
most common neurologic injury.4 In contrast to 
overt stroke (hereinafter referred to as stroke), a 
silent cerebral infarct is not associated with ob-
vious neurologic impairment and cannot be de-
tected on neurologic examination.5 However, chil-
dren with a silent cerebral infarct are at increased 
risk for stroke, new or enlarged silent cerebral 
infarcts,6 poor academic achievement,7 and lower 
IQ, as compared either with children with sickle 
cell anemia who have normal results on magnetic 
resonance imaging (MRI) of the brain or with 
siblings without sickle cell anemia.7,8
The most effective therapy for children with 
sickle cell anemia and silent cerebral infarcts is 
unknown. For the primary prevention of stroke, 
the Stroke Prevention Trial in Sickle Cell Anemia 
(STOP) showed that regular blood-transfusion 
therapy was efficacious.9 Given the favorable re-
sults of a single-group feasibility trial,10 coupled 
with the high prevalence and progressive nature 
of silent cerebral infarction, a critical unanswered 
question is whether regular blood-transfusion 
therapy in children with silent cerebral infarcts 
prevents the recurrence of an infarct (stroke or 
new or enlarged silent cerebral infarct). In the 
Silent Cerebral Infarct Multi-Center Clinical Trial 
(SIT), we tested the primary hypothesis that the 
incidence of infarct recurrence would be lower 
among children receiving regular blood-transfu-
sion therapy than among children assigned to 
standard care.
Me thods
Trial Oversight
SIT was a multicenter, randomized clinical trial 
in which we assigned children with sickle cell 
anemia–related silent cerebral infarcts to receive 
standard care (observation group) or regular blood-
transfusion therapy (transfusion group). A de-
tailed description of the study protocol has been 
published previously,11 and the protocol is avail-
able with the full text of this article at NEJM.org. 
The study was conducted at 29 clinical centers in 
the United States, Canada, France, and the United 
Kingdom. The trial was approved by the institu-
tional review board at each participating institu-
tion. The first two authors analyzed the data and 
vouch for the accuracy and completeness of the 
data, and the first author vouches for the fidelity 
of the study to the protocol. A data and safety 
monitoring board appointed by the National In-
stitute of Neurological Disorders and Stroke re-
viewed serious adverse events, study progress, and 
safety every 6 months. The last participant en-
rolled completed the exit visit on July 29, 2013. 
Data were adjudicated and the database was 
locked for this report on September 1, 2013.
Participants
Inclusion criteria were an age of 5 to 15 years, 
confirmed diagnosis of hemoglobin SS or hemo-
globin Sβ0 thalassemia, and at least one infarct-
like lesion on the screening MRI scan. Written 
informed consent was obtained from parents or 
legal guardians and assent from the study partici-
pants. An infarct-like lesion was defined as an 
MRI signal abnormality that was at least 3 mm 
in one dimension and that was visible in two 
planes on fluid-attenuated inversion recovery 
(FLAIR) T2-weighted images, as determined by 
agreement of two of the three study neuroradi-
ologists. The members of a neurology commit-
tee adjudicated a lesion as a silent cerebral in-
farct if the study participant had either a normal 
neurologic examination or an abnormality on 
examination that could not be explained by the 
location of the brain lesion or lesions. Exclusion 
criteria were a history of focal neurologic deficit 
associated with an infarct on brain MRI, a sei-
zure disorder, treatment with hydroxyurea in the 
previous 3 months, a history of regular transfu-
sion therapy, or imaging or nonimaging tran-
scranial Doppler measurement that was above 
the study-defined thresholds.11
Study Design
Randomization assignments were provided by 
the statistical data coordinating center with the 
use of a permuted block design, with stratification 
according to site, age, and sex. Participants were 
assigned in a 1:1 ratio to the observation group 
or the transfusion group and were followed until 
the occurrence of a study end-point event or until 
exit from the study. At baseline and exit, partici-
pants underwent brain MRI and neurologic and 
cognitive examinations. If a neurologic event was 
suspected during the study, MRI and neurologic 
examination were performed.
Participants who were randomly assigned to 
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observation received standard care (with no treat-
ment for silent infarcts, including no hydroxy-
urea therapy) and were evaluated quarterly. Par-
ticipants who were randomly assigned to the 
transfusion group received a transfusion approxi-
mately monthly to maintain a target hemoglobin 
concentration greater than 9.0 g per deciliter and 
a target hemoglobin S concentration of 30% or 
less of total hemoglobin. Ferritin levels were 
monitored before each transfusion. Site investi-
gators were advised to initiate chelation therapy 
for participants who had ferritin levels greater 
than 1500 ng per milliliter for 2 or more con-
secutive months.
Primary and Secondary End Points
The primary end point was the recurrence of 
infarct or hemorrhage as determined by neuro-
imaging, clinical evidence of permanent neuro-
logic injury, or both. A new infarct had to meet 
the criteria for a silent cerebral infarction; an 
enlarged silent cerebral infarct was defined as a 
previously identified silent cerebral infarct that 
increased by at least 3 mm along any linear dimen-
sion in any plane on MRI. A transient ischemic 
attack (TIA), which was included in secondary 
analyses of neurologic outcomes, was defined as 
an event that resulted in focal neurologic deficits 
that lasted less than 24 hours, did not result in 
abnormalities on T2-weighted or FLAIR images 
that were indicative of an acute infarct, and had 
no other reasonable medical explanation. Members 
of neuroradiology and neurology committees, who 
were unaware of the study-group assignments, 
adjudicated neurologic and MRI findings. Second-
ary outcomes included changes in cognition, 
which were assessed by measurement of IQ 
scores with the Wechsler Abbreviated Scale of 
Intelligence12 or the Wechsler Preschool and Pri-
mary Scale of Intelligence III.13 We also assessed 
scores on the Behavior Rating Inventory of Ex-
ecutive Function (BRIEF).14
Statistical Analysis
To test the primary hypothesis, we calculated that 
a sample size of 204 participants (102 in each 
group) would give the study 85% power to detect 
a decrease of at least 86% in the prevalence of 
the primary end point, assuming a 10% dropout 
rate and a crossover rate of 16% from transfusion 
to observation and 3% from observation to trans-
fusion, at a two-tailed nominal alpha level of 0.05. 
In 2012, the data and safety monitoring board ap-
proved the use of rate ratio to test the primary 
hypothesis in order to adjust for variable expo-
sure time. For the primary hypothesis, the inten-
tion-to-treat principle was used to compare inci-
dence rates of infarct recurrence between the 
transfusion group and the observation group. A 
parallel analysis comparing the two study groups 
with respect to all neurologic outcomes (i.e., in-
farct recurrence plus TIA) was also conducted. We 
tested the null hypotheses (incidence ratio = 1.0) 
and estimated exact 95% confidence intervals by 
using bootstrap methods with 10,000 replica-
tions. P values were estimated with the use of a 
permutation test. Logistic regression models were 
used to adjust for an imbalance in baseline fac-
tors and to determine whether prespecified factors 
(as listed in the Supplementary Appendix, avail-
able at NEJM.org) were associated with infarct 
recurrence.
R esult s
Recruitment and Baseline Characteristics
Recruitment began in December 2004 and con-
tinued through the end of May 2010. Among the 
1074 children who underwent screening MRI of 
the brain, 20 (1.9%) had strokes and 379 (35.3%) 
had infarct-like lesions. Two participants with 
results of imaging transcranial Doppler studies 
of 199 cm per second and 196 cm per second, 
which were above the eligibility threshold, inad-
vertently underwent randomization because a pro-
gramming error failed to distinguish between 
imaging and nonimaging transcranial Doppler 
studies. Both participants were assigned to the 
observation group; a stroke occurred in one of 
them. Table 1 shows the baseline characteristics 
of the participants, and Figure 1 the screening, 
randomization, and follow-up.
Intervention
The primary end point was ascertained for 185 
of the 196 participants (94%). Of the 99 partici-
pants randomly assigned to the transfusion group, 
90 started receiving transfusions within 4 weeks 
after assignment. The crossover rate from trans-
fusion to observation was 15% (15 of 99 partici-
pants); 9 participants declined blood transfusion, 
and 6 crossed over to observation at a median 
time of 34 days. Among the 90 participants in the 
transfusion group who received transfusions, 
the interval between transfusions was 38 days or 
less for 95% of the 3236 transfusions, and the 
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Characteristic
Observation Group 
 (N = 97)
Transfusion Group 
 (N = 99)
Age — no. (%)†
5–7 yr 28 (29) 26 (26)
8–10 yr 32 (33) 35 (35)
11–13 yr 29 (30) 32 (32)
14–15 yr 8 (8) 6 (6)
Sex — no. (%)
Male 52 (54) 59 (60)
Female 45 (46) 40 (40)
Race — no. (%)‡
Black 90 (93) 91 (92)
White 0 2 (2)
Other 7 (7) 6 (6)
Results of transcranial Doppler assessment 
 — no. (%)§
Normal 82 (85) 76 (77)
Conditional 13 (13) 22 (22)
High 2 (2) 0
Assessment attempted but unsuccessful 0 1 (1)
Parental report of recurring headaches — no. (%)
Yes 43 (44) 37 (37)
No 54 (56) 62 (63)
Transcranial Doppler velocity during screening¶
No. of patients with data 97 98
Median (IQR) — cm/sec 143 (131–163) 147 (123–168)
Hospital admissions for pain∥
No. of patients with data 97 99
Median (IQR) — rate per 100 person-yr 33.3 (0–100.0) 33.3 (0–66.7)
Hospital admissions for acute chest syndrome∥
No. of patients with data 97 99
Median (IQR) — rate per 100 person-yr 0 (0–33.3) 0 (0–33.3)
Steady-state hemoglobin
No. of patients with data 97 99
Median (IQR) — g/dl 7.9 (7.4–8.9) 7.7 (7.2–8.4)
Steady-state reticulocytes
No. of patients with data 95 96
Median (IQR) — % 10.3 (7.7–13.6) 12.3 (9.6–16.2)
Highest total bilirubin in previous 3 years
No. of patients with data 88 92
Median (IQR) — mg/dl 2.8 (1.9–3.9) 2.9 (1.9–4.7)
Hemoglobin F**
No. of patients with data 86 94
Median (IQR) — % 10.0 (5.0–15.0) 9.0 (4.0–14.0)
Steady-state white-cell count
No. of patients with data 97 99
Median (IQR) — per mm3 12,500 (10,000–14,700) 12,300 (10,000–15,000)
Steady-state neutrophils
No. of patients with data 92 94
Median (IQR) — % 47.0 (38.0–59.0) 47.5 (42.0–57.0)
Table 1. Baseline Characteristics of the Participants.*
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median hemoglobin S level was 30.1% (Fig. 2A). 
Ferritin levels are shown in Figure 2B. Among 
participants in the observation group, 32% re-
ceived transfusions (a median of three transfusions 
each), including 6 participants who crossed over to 
regular monthly transfusions at a median of 1.7 
years. During the course of the trial, hydroxyurea 
was started in 14 of 97 participants (14%) in the 
observation group and in 3 of 99 (3%) in the trans-
fusion group because of disease severity.
Neurologic Outcomes
Exit MRIs were completed for 185 of the 196 par-
ticipants (94%). In the transfusion group, 99 
participants accumulated 304 patient-years (me-
dian, 3.0 years per patient); in the observation 
group, 97 participants accumulated 289 patient-
years (median, 3.0 years per patient). The preva-
lence of the primary end point was 6% (6 of 99 
participants) in the transfusion group and 14% 
(14 of 97 participants) in the observation group 
(Table 2).
In an intention-to-treat analysis, the incidence 
rate of infarct recurrence was 2.0 per 100 person-
years at risk in the transfusion group and 4.8 per 
100 person-years at risk in the observation group, 
with an incidence rate ratio of 0.41 (95% confi-
dence interval [CI], 0.12 to 0.99; P = 0.04). The 
absolute risk reduction was 8 percentage points, 
the relative risk reduction was 58%, and the num-
ber needed to treat for 3 years to prevent one 
recurrence of infarct was 13.
Three TIAs occurred, all in the observation 
group, including a TIA in one participant who 
subsequently had a stroke. Adding TIA events to 
infarct recurrence, the incidence rate of all neu-
rologic events in the transfusion and observation 
groups was 2.0 and 5.6 per 100 person-years at 
risk, respectively, with an incidence rate ratio of 
0.36 (95% CI, 0.10 to 0.83; P = 0.02).
Fifteen postulated risk factors for infarct re-
currence were evaluated, of which four were 
significant. The odds ratio for infarct recurrence 
in the transfusion group as compared with the 
Characteristic
Observation Group 
 (N = 97)
Transfusion Group 
 (N = 99)
Steady-state platelets
No. of patients with data 96 99
Median (IQR) — per mm3 438,500 (364,000–519,500) 423,000 (372,000–509,000)
Systolic blood pressure
No. of patients with data 97 99
Median (IQR) — mm Hg 108.0 (103.0–117.0) 107.0 (102.0–115.0)
Oximetry reading
No. of patients with data 96 95
Median (IQR) — % 97.0 (95.0–99.0) 97.0 (94.0–98.0)
*  The baseline characteristics were determined at the time of initial screening. There were no significant differences in 
baseline characteristics except with respect to the reticulocyte count, for which P = 0.002. IQR denotes interquartile 
range.
†  The age listed is the age at the time of randomization rather than the age at the time of initial screening.
‡  Race was self-reported.
§  For imaging transcranial Doppler assessment, 0 to less than 155 cm per second was considered to be normal, 155 to 
less than 185 cm per second was considered to be conditional, and 185 cm per second or higher was considered to 
be high. For nonimaging transcranial Doppler, 0 to less than 170 cm per second was considered to be normal, 170 to 
less than 200 cm per second was considered to be conditional, and 200 cm per second or higher was considered to 
be high.
¶  To standardize the report to nonimaging transcranial Doppler measurements, we added 15 points to the results of 
imaging transcranial Doppler measurements.
∥  The mean rate of hospital admissions for pain was 68.7 per 100 person-years in the observation group and 62.3 per 
100 person-years in the transfusion group. The mean rate of hospital admissions for the acute chest syndrome was 
19.6 per 100 person-years in the observation group and 16.2 per 100 person-years in the transfusion group.
**  Data on hemoglobin F at baseline were categorized as missing if the test was performed before the participant was  
3 years of age or if the test was not performed.
Table 1. (Continued.)
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observation group was 0.31 (95% CI, 0.10 to 0.93; 
P = 0.04). Baseline factors associated with infarct 
recurrence were younger age (odds ratio, 1.41; 
95% CI, 1.12 to 1.78; P = 0.004), a history of recur-
ring headaches (odds ratio, 4.33; 95% CI, 1.50 to 
13.06; P = 0.007), and a higher steady-state reticu-
locyte count (odds ratio, 1.11; 95% CI, 1.01 to 1.22; 
P = 0.04) (Table S3 in the Supplementary Appen-
Figure 1. Screening, Randomization, and Follow-up.
The screening and randomization process extended from December 2004 through May 2010. Participants may have 
had more than one reason for exclusion or withdrawal from the study. For participants who were lost to follow-up, 
data that had accrued before withdrawal were used in the analysis.
1074 Had screening MRI evaluated
by neuroradiology committee
1210 Children were registered for screening
86 Did not have a screening
MRI or had a screening MRI
that could not be evaluated
379 Had infarct-like lesions detected
on screening MRI adjudicated
by neuroradiology committee
291 Had infarct-like lesions adjudicated
by neurology committee
220 Had prerandomization MRIs adjudi-
cated by neuroradiology committee
196 Underwent randomization
99 Were assigned to tranfusion
90 Received ≥1 transfusions
97 Were assigned to observation
97 Were observed
96 Were withdrawn by
principal investigator
69 Declined to participate
27 Had time-commitment
constraints
6 Relocated
6 Had financial constraints
123 Had other screening
failures or withdrew
675 Had normal MRI
20 Had indeterminate MRI
20 Had overt strokes
8 Had new or enlarged
infarct-like lesions
1 Had stroke
5 Had new or enlarged silent cerebral
infarcts
7 Had strokes
7 Had new or enlarged silent cerebral
infarcts
2 Had transient ischemic attacks only
15 Crossed over to observation
9 Declined transfusion immediately 
   after randomization
6 Received transfusion and then 
   crossed over to observation 
6 Crossed over to transfusion
99 Were included in the analysis
2 Were lost to follow-up or withdrew
97 Were included in the analysis
9 Were lost to follow-up or withdrew
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dix). No significant changes in full-scale IQ or 
BRIEF measurements were observed from base-
line to study exit, either within or between the 
observation and transfusion groups (Tables S1 
and S2 in the Supplementary Appendix).
Adverse Events
Incidence rates of vaso-occlusive pain, acute chest 
syndrome, priapism, and new symptomatic avas-
cular necrosis of the hip were significantly higher 
in the observation group than in the transfusion 
group (Table 3). Transfusion reactions were re-
ported in 1 participant (1%) in the observation 
group and in 15 of the 90 participants (17%) in 
the transfusion group who actually received blood-
transfusion therapy; 9 participants had one reac-
tion, 6 had two reactions, and 1 had four reactions. 
Most reactions were allergic (13 of 25 [52%]) or 
febrile nonhemolytic (8 of 25 [32%]) reactions. A 
tunneled central venous catheter for vascular ac-
cess was implanted in 11 participants; a catheter 
infection developed in 1 of these participants, 
and complications requiring catheter replacement 
developed in 2 others. A total of 3236 transfu-
sions were administered in the transfusion group, 
and nine alloantibodies were detected in 4 par-
ticipants — anti-C (in 2 participants), anti-V (in 
2 participants), anti-FyA, anti-e, anti-S, anti-JK-b, 
and anti-Wra — for an alloimmunization rate of 
0.278 per 100 units of red cells. No alloantibodies 
were detected among participants in the obser-
vation group. No deaths occurred.
Discussion
Silent cerebral infarcts have only recently been 
recognized as an important clinical complication 
of sickle cell anemia. Despite the high prevalence 
of silent cerebral infarcts4 and their association 
with lower IQ,8,15 poor academic performance,7 and 
increased risk for stroke,16 no evidence-based 
approach has been developed to systematically 
identify and treat children with silent cerebral 
infarcts. The primary results of our study indi-
cate that children with sickle cell anemia, silent 
cerebral infarcts, and normal transcranial Dop-
pler measurements will have a 58% relative risk 
reduction in the recurrence of infarcts while they 
are receiving regular blood-transfusion therapy.
The benefits of blood-transfusion therapy for 
the secondary prevention of infarct recurrence in 
SIT are substantial but are lower than those in 
STOP,9 which also used blood transfusion for the 
primary prevention of stroke. In STOP, the rela-
tive risk reduction was 92%.9 Although the benefit 
of blood-transfusion therapy in preventing infarct 
recurrence in children with silent cerebral in-
farcts is lower than the benefit of blood transfu-
sions for primary stroke prevention, the preva-
lence of silent cerebral infarcts (which occur in 
approximately 33% of children with sickle cell 
anemia) is much higher than the prevalence of 
abnormal transcranial Doppler studies (approxi-
mately 10% in an unscreened population17). Thus, 
a greater number of children with silent cerebral 
infarcts are expected to benefit from blood-trans-
fusion therapy.
Among children with preexisting silent cere-
bral infarcts, the precise mechanisms whereby 
regular blood transfusions decrease the incidence 
of infarct recurrence are unclear. Previously pub-
lished data from SIT indicate that children in the 
lowest quartile of hemoglobin levels at baseline 
have higher odds of silent cerebral infarct than 
do those in the top quartile.18 Furthermore, chil-
dren with sickle cell anemia, all of whom have 
chronic anemia, have evidence of ongoing sub-
clinical ischemic injury.19 Acute reduction in he-
moglobin concentration (<5.5 g per deciliter) in 
hospitalized children is temporally associated with 
an increase in new-onset silent cerebral infarcts, 
whether or not the child has sickle cell anemia.20 
These findings suggest that the pathogenesis of 
silent cerebral infarcts could be explained in 
part by acute or chronic anemia with cerebral 
hemodynamic decompensation.21 Regular blood-
transfusion therapy partially corrects the anemia 
and attenuates the risk of infarct recurrence, 
possibly by improving cerebrovascular reserve.
The timing for detecting silent cerebral in-
farcts is unclear. In a small study, the prevalence 
of silent cerebral infarcts at an average age of 
13.7 months was 13%.22 In a second study, in 
which surveillance MRI was conducted among 
children up to 6 years of age, the prevalence of 
silent cerebral infarct was 27%.23 In a third study, 
the prevalence by 14 years of age was 37%.4 Thus, 
the majority of silent cerebral infarcts have oc-
curred in children with sickle cell anemia by 6 years 
of age. However, performing MRI of the brain 
among children younger than 6 years of age often 
requires sedation. In SIT, the youngest age for 
evaluating silent cerebral infarcts was 5 years, 
and in the observation group, younger children 
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were more likely than older children to have in-
farct recurrence. These findings suggest that, at 
a minimum, one surveillance MRI of the brain, 
preferably without sedation, should be performed 
in children with sickle cell anemia who are be-
ginning elementary school.
Detecting silent cerebral infarcts in children 
is particularly important owing to the predicted 
effects on cognition and now the evidence from 
this trial that infarct recurrence can be prevent-
ed in most children. IQ scores in children with 
silent cerebral infarcts are 5 points lower than 
Figure 2 (facing page). Hemoglobin S and Ferritin  
Levels in the Transfusion Group.
The box plots show the hemoglobin S levels (Panel A) 
and the ferritin levels (Panel B) in the transfusion 
group, in 6-month intervals. The horizontal line in the 
boxes represents the median, the lower and upper 
boundaries of the boxes represent the 25th and 75th 
percentiles, respectively, the I bars represent the 10th 
and 90th percentiles, and the circles represent values 
outside the 10th and 90th percentiles. The number of 
participants listed does not include nine participants 
who declined transfusion therapy immediately after 
they underwent randomization.
Patient No.
Time from 
Randomization  
to End Point
End-Point  
Classification
Neuroradiology  
Finding† TIA† Baseline Clinical Characteristics
New  
Infarct
Enlarged 
Infarct Age‡
Systolic Blood 
Pressure
Steady-State  
Hemoglobin Hemoglobin F§
mo yr mm Hg g/dl %
Transfusion group
1 24 Stroke + − − 7.9 107 6.7 4
2 35 SCI + + − 8.5 85 9.8 17
3 36 SCI + + − 7.5 101 10.3 19
4 36 SCI + + − 9.3 107 7.9 13
5 39 SCI + − − 9.1 92 7.5 2
6 36 SCI − + − 8.3 107 7.2 10
Observation group
7 6 Stroke + + − 7.8 106 7.9 NA
8 19 Stroke + − − 6.7 106 7.8 NA
9 30 Stroke + − − 12.7 122 6.7 NA
10 36 Stroke + − − 7.3 93 7.5 4
11 12 Stroke − + − 6.6 107 8.0 9
12 19 Stroke − − + 7.1 96 6.5 18
13 35 Stroke − − − 10.3 100 6.1 0
14 16 SCI + − − 8.0 110 7.7 8
15 27 SCI + − − 6.3 103 8.4 NA
16 34 SCI + − − 6.9 107 7.7 18
17 37 SCI + − − 6.7 109 8.0 25
18 41 SCI + − − 12.7 118 6.9 4
19 41 SCI + − − 6.7 112 9.4 9
20 44 SCI + − − 9.6 120 10.2 16
21 12 TIA − − + 12.3 136 7.7 13
22 13 TIA − − + 7.1 87 8.6 15
*  The baseline characteristics were determined at the time of initial screening. NA denotes not available, SCI silent cerebral infarct, and TIA 
transient ischemic attack.
†  A plus sign indicates that the end-point event occurred, and a minus sign that the end-point event did not occur.
‡  The age listed is the age at randomization rather than the age at the time of initial screening.
§  Data on hemoglobin F at baseline were categorized as not available (NA) if the test was performed before the participant was 3 years of age 
or if the test was not performed.
Table 2. Neurologic Events and Baseline Characteristics, According to Patient.*
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those in children without silent cerebral in-
farcts,24 which corresponds to a 5 to 9% reduc-
tion in annual income as adults.25 If silent cere-
bral infarcts are detected at the time children 
begin elementary school, cognitive difficulties 
may be identified and academic support initiat-
ed. Although our results did not show that in-
farct recurrence was associated with decreased 
IQ scores, the absence of a change in IQ scores 
must be interpreted cautiously, because infarct 
recurrence occurred in only 10% of our partici-
pants. In addition, specific cognitive measures 
such as executive function, attention, and mem-
ory might have been more sensitive than mea-
surements of IQ to change associated with in-
farct recurrence.
After detection of a silent cerebral infarct, 
treatment options can be discussed with families, 
including the benefits of regular blood-transfu-
sion therapy (decreased incidences of cerebral 
infarct recurrence, pain events necessitating hos-
pitalization, priapism, avascular necrosis, and 
acute chest syndrome), associated risks (exces-
sive iron stores, the need for chelation therapy, 
transfusion reactions, central venous catheter 
placement, and red-cell alloimmunization), and 
burdens (monthly clinic visits with associated 
missed school and work time). The duration of 
Adverse Event
Sample  
Size
At Least 1 
 Adverse  
Event
Total  
Adverse  
Events
At-Risk  
Time
Adverse Events/ 
100 Person-Yr
Incidence Rate Ratio 
 (95% CI)* P Value
no. of participants no. person-yr
Vaso-occlusive pain 0.41 (0.20–0.75) 0.004
Observation group 97 56 295 289 102.21
Transfusion group 99 32 126 304 41.58
Acute chest syndrome 0.13 (0.04–0.28) <0.001
Observation group 97 24 41 289 14.35
Transfusion group 99 5 5 304 1.81
Priapism† 0.13 (0.03–0.55) 0.02
Observation group 52 7 10 158 6.65
Transfusion group 59 1 1 178 0.84
Symptomatic avascular 
necrosis of the hip
0.22 (0.05–0.85) 0.02
Observation group 97 6 6 289 2.25
Transfusion group 99 1 1 304 0.49
Headache 0.78 (0.39–1.57) 0.40
Observation group 97 30 93 289 32.34
Transfusion group 99 24 76 304 25.15
Blood-transfusion reaction 5.33 (1.67–23.52) 0.05
Observation group 31‡ 1 1 90 1.66
Transfusion group 90§ 15 24 277 8.85
Ferritin >1500 ng/ml 14.42 (5.41–875.17) <0.001
Observation group 31‡ 3 33 90 37.07
Transfusion group 90§ 76 1479 277 534.70
*  The incidence ratio was calculated as the rate of adverse events per 100 person-years in the transfusion group divided by the rate of adverse 
events per 100 person-years in the observation group. The 95% confidence intervals were calculated with the use of the bootstrap method 
with 10,000 replications.
†  This event was documented in male participants only.
‡  A total of 31 participants who were randomly assigned to observation received one or more transfusions.
§  A total of 9 participants who declined transfusions were excluded from this analysis.
Table 3. Incidence of Adverse Events in the Observation and Transfusion Groups per 100 Person-Years.
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blood-transfusion therapy for the secondary pre-
vention of silent cerebral infarcts is unknown, 
but results from SIT suggest that a minimum of 
3 years of therapy should be considered.
To prevent alloimmunization, every effort was 
made to ensure that participants were matched 
for red-cell antigens that are most commonly 
associated with antibody formation in sickle cell 
disease.26 Alloimmunization occurred despite these 
efforts but was infrequent. The rate of alloim-
munization was similar to that in a previous clini-
cal trial involving participants with sickle cell 
disease that used identical minor red-cell antigen 
matching.27
The results of SIT are not directly applicable 
to all children with sickle cell anemia, because 
children who were receiving hydroxyurea thera-
py for severe disease, had elevated transcranial 
Doppler measurements, were receiving blood 
transfusions for primary stroke prevention, or 
had epilepsy were excluded. More than 15% of 
the children assigned to the transfusion group 
(15 of 99 children) never received effective ther-
apy. Despite the fact that 9 participants who were 
randomly assigned to the transfusion group de-
clined transfusion therapy immediately after as-
signment and 6 in that group crossed over to the 
observation group at a median of 34 days, the 
incidence rate for infarct recurrence was signifi-
cantly lower among participants in the transfu-
sion group than among participants in the ob-
servation group. A greater therapeutic effect might 
have been observed if treatment had been re-
ceived for 36 months by all the participants who 
had been randomly assigned to receive blood-
transfusion therapy.
In summary, blood-transfusion therapy re-
duced the incidence of infarct recurrence among 
children with sickle cell anemia who had silent 
cerebral infarcts. Research is needed to identify 
the children with silent cerebral infarcts who are 
at greatest risk for infarct recurrence, so that 
transfusion therapy can be targeted specifically 
to these children.
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